sofosbuvir + simeprevir + daclatasvir + ribavirin

This is a combination therapy consisting of four medications that work together to treat chronic hepatitis C virus (HCV) infection. The regimen is particularly used for patients who have failed previous direct-acting antiviral (DAA) treatments, especially those with difficult-to-treat genotypes or with advanced liver disease. Each component has a specific role in combating HCV: - **Sofosbuvir** is a nucleotide analog NS5B polymerase inhibitor that blocks the hepatitis C NS5B protein, preventing viral replication - **Simeprevir** targets the viral NS3/4A protease - **Daclatasvir** inhibits the NS5A protein essential for viral replication - **Ribavirin** is a broad-spectrum antiviral that enhances the effectiveness of the other medications This quadruple therapy approach is recommended in current guidelines for DAA-experienced patients despite limited clinical data. Studies have shown high sustained virological response (SVR) rates, particularly when treatment duration is adjusted based on the patient's fibrosis stage. Clinical studies have demonstrated that this combination can achieve SVR rates of 96-100% in patients with less advanced fibrosis (F1 and F2) and 96-97% in patients with more advanced fibrosis (F3 and F4)[6]. The treatment duration typically ranges from 12 weeks for patients with minimal fibrosis to 24 weeks for those with advanced fibrosis or cirrhosis. Side effects may include fatigue, headache, nausea, insomnia, and rash. In some cases, serious adverse events have led to treatment discontinuation, particularly in patients with cirrhosis. This combination has several important drug interactions to consider: - Should not be used with amiodarone due to risk of abnormally slow heartbeat - Inducers of P-glycoprotein (like rifampicin and St. John's wort) may reduce sofosbuvir absorption - Coadministration with anticonvulsants, antimycobacterials, and certain HIV protease inhibitors is not recommended This is a combination therapy consisting of four direct-acting antiviral medications used to treat chronic hepatitis C virus (HCV) infection. The regimen is particularly valuable for patients who have failed previous direct-acting antiviral treatments, especially those with difficult-to-treat genotypes or with advanced liver disease. Each component has a specific mechanism of action: - **Sofosbuvir**: A nucleotide analog NS5B polymerase inhibitor that blocks the hepatitis C NS5B protein, preventing viral replication - **Simeprevir**: An NS3/4A protease inhibitor that prevents viral polyprotein processing - **Daclatasvir**: An NS5A inhibitor that interferes with viral replication and assembly - **Ribavirin**: A broad-spectrum antiviral that enhances the effectiveness of the other medications through multiple mechanisms Clinical studies have demonstrated high sustained virological response (SVR) rates with this combination, particularly when treatment duration is adjusted based on the patient's fibrosis stage.

Other names

sofosbuvir + simeprevir + daclatasvir + ribavirin quadruple therapySOF + SMV + DCV + RBV